KURA Stock Overview
A clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Kura Oncology, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$8.86 |
| 52 Week High | US$24.17 |
| 52 Week Low | US$8.75 |
| Beta | 0.76 |
| 1 Month Change | -17.96% |
| 3 Month Change | -54.73% |
| 1 Year Change | -36.76% |
| 3 Year Change | -41.17% |
| 5 Year Change | -35.56% |
| Change since IPO | -40.93% |
Recent News & Updates
Kura Oncology Presents Deep Value At Today's Prices (Rating Upgrade)
Dec 18Kura Oncology: A Contender In The Field Of Precision Medicine
Nov 21Kura Oncology (NASDAQ:KURA) Has Debt But No Earnings; Should You Worry?
Nov 01
Recent updates
Kura Oncology Presents Deep Value At Today's Prices (Rating Upgrade)
Dec 18Kura Oncology: A Contender In The Field Of Precision Medicine
Nov 21Kura Oncology (NASDAQ:KURA) Has Debt But No Earnings; Should You Worry?
Nov 01Kura Oncology: The Long Holding Pattern Is Risky
Aug 12Estimating The Fair Value Of Kura Oncology, Inc. (NASDAQ:KURA)
Jul 12Is Kura Oncology (NASDAQ:KURA) Using Debt Sensibly?
May 08Kura Oncology: Balancing Act Of Promise And Pragmatism
May 07Kura Oncology: Ziftomenib's Path To AML Market Widens
Jan 31Kura Oncology, Inc.'s (NASDAQ:KURA) Intrinsic Value Is Potentially 72% Above Its Share Price
Jan 25Is Kura Oncology (NASDAQ:KURA) A Risky Investment?
Aug 14Is Kura Oncology (NASDAQ:KURA) Using Debt Sensibly?
Apr 04Is There An Opportunity With Kura Oncology, Inc.'s (NASDAQ:KURA) 44% Undervaluation?
Jan 31Kura Oncology (NASDAQ:KURA) Is In A Good Position To Deliver On Growth Plans
Oct 10Kura Oncology stock rises 7% as Cantor Fitzgerald begins coverage with Overweight rating
Jul 13We Think Kura Oncology (NASDAQ:KURA) Can Afford To Drive Business Growth
Jun 26We're Not Very Worried About Kura Oncology's (NASDAQ:KURA) Cash Burn Rate
Nov 23We're Not Very Worried About Kura Oncology's (NASDAQ:KURA) Cash Burn Rate
Aug 09Kura Oncology Investor Presentation - Slideshow
May 08What Kind Of Shareholders Hold The Majority In Kura Oncology, Inc.'s (NASDAQ:KURA) Shares?
Dec 14
Kura Oncology: Advanced Precision Medicine Opportunity Excites, But Not Without Risks
Dec 10Kura Oncology (KURA) Presents At ASH Virtual Investor Event
Dec 08Shareholder Returns
| KURA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -9.0% | -3.3% | -0.4% |
| 1Y | -36.8% | -2.7% | 24.8% |
Return vs Industry: KURA underperformed the US Biotechs industry which returned -1.9% over the past year.
Return vs Market: KURA underperformed the US Market which returned 23.9% over the past year.
Price Volatility
| KURA volatility | |
|---|---|
| KURA Average Weekly Movement | 11.6% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: KURA's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: KURA's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 142 | Troy Wilson | kuraoncology.com |
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.
Kura Oncology, Inc. Fundamentals Summary
| KURA fundamental statistics | |
|---|---|
| Market cap | US$688.99m |
| Earnings (TTM) | -US$197.55m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-3.5x
P/E RatioIs KURA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KURA income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$197.55m |
| Earnings | -US$197.55m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.54 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 2.2% |
How did KURA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/24 07:15 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Kura Oncology, Inc. is covered by 21 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Peter Lawson | Barclays |
| Jason Zemansky | BofA Global Research |
| Leah Rush Cann | Brookline Capital Markets |